

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Next-generation prime-boost HIV vaccine	<p>A study in monkeys identified a prime and boost regimen that could be useful for vaccination against HIV infection. Macaques were vaccinated with combinations of modified vaccinia Ankara (MVA) and adenovirus serotype 26 (Ad26). An Ad26 prime and MVA boost regimen provided protection against repeated intra-rectal inoculation with a highly virulent strain of simian immunodeficiency virus (SIV) compared with other prime-boost combinations. Next steps include scaling up manufacturing of the vaccine formulation in preparation for an investigator-initiated Phase I trial. Johnson & Johnson's Crucell N.V. unit coauthored the study and is manufacturing this vaccine.</p> <p>SciBX 5(4); doi:10.1038/scibx.2012.111 Published online Jan. 26, 2012</p>	<p>Multiple components of the vaccine used in this study covered by patents held by various companies and institutions; licensing status undisclosed</p>	<p>Barouch, D.H. <i>et al. Nature</i>; published online Jan. 4, 2012; doi:10.1038/nature10766 Contact: Dan H. Barouch, Harvard Medical School, Boston, Mass. e-mail: dbarouch@bidmc.harvard.edu</p>